[HTML][HTML] Bisphosphonates for osteoporosis—where do we go from here?
M Whitaker, J Guo, T Kehoe… - New England Journal of …, 2012 - Mass Medical Soc
M Whitaker, J Guo, T Kehoe, G Benson
New England Journal of Medicine, 2012•Mass Medical SocBisphosphonates for Osteoporosis — Where Do We Go from Here? | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career with
NEJM Group information and services. NEJM Evidence NEW! A digital journal for innovative
original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career with
NEJM Group information and services. NEJM Evidence NEW! A digital journal for innovative
original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
In response to reports of rare but serious adverse events associated with bisphosphonates, the FDA reviewed long-term bisphosphonate efficacy. Two FDA committees recommended an update to bisphosphonate labeling but no regulatory restriction on duration of use.
The New England Journal Of Medicine